<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060423</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2009-014728-44</org_study_id>
    <nct_id>NCT01060423</nct_id>
  </id_info>
  <brief_title>TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer</brief_title>
  <acronym>DEBIRITUX</acronym>
  <official_title>A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hans-Joachim Schmoll, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in
      combination with intravenous cetuximab versus intravenous irinotecan in combination with
      intravenous cetuximab in the treatment of patients with unresectable liver metastases from
      colorectal cancer.

      Secondary objectives are safety and tolerability of hepatic chemoembolization and the
      question if the addition of aprepitant to standard antiemetic prophylaxis in patients treated
      by hepatic chemoembolization is safe and will reduce the rate of acute and delayed nausea and
      emesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About half of patients with newly diagnosed colorectal cancer will develop metastatic disease
      and, however, in spite of the significant progress in the therapeutical strategies for
      metastatic disease, virtually all patients will eventually succumb to their illness. Based on
      prior clinical data there is a good rationale for the expectation that the combination of
      systemic chemotherapy and arterial chemoembolization with drug eluting beads may be effective
      in the setting of patients with unresectable or chemorefractory liver metastases. The aim of
      this study is therefore to assess whether the combination of Irinotecan eluting beads and
      intravenous cetuximab is safe and effective in the treatment of patients with unresectable
      liver metastases from refractory colorectal cancer and will result in a prolongation of
      disease control when compared to standard systemic treatment with intravenous irinotecan and
      intravenous cetuximab. In this patient group, intravenous irinotecan plus intravenous
      cetuximab may represent the &quot;standard of care&quot;, with a previously described activity. The
      patient group is defined in terms of pretreatment, and the scientific question is whether the
      way of irinotecan administration by eluting beads in feasible and somehow beneficial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to poor subject enrolment
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>6 months after first administration of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour Response (according to RECIST v1.1)</measure>
    <time_frame>every three months up to progression of disease, maximum 12 months from the date of patient enrolment</time_frame>
    <description>extent of treated lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>every three months, until death of patient, maximum 12 months from the date of patient enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in study patients</measure>
    <time_frame>whole study, every two weeks until 28 days from the date of last administration of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tumour response</measure>
    <time_frame>every three months up to progression of disease, maximum 12 months from the date of patient enrolment</time_frame>
    <description>extent of necrosis in the treated lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every three months, until death of patient, maximum 12 months from the date of last patient enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>hepatic TACE with irinotecan eluting beads and iv cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iv cetuximab and irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systemic treatment with intravenous cetuximab and irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Starting dose of 400mg/m2, followed by weekly 250mg/m2</description>
    <arm_group_label>hepatic TACE with irinotecan eluting beads and iv cetuximab</arm_group_label>
    <arm_group_label>iv cetuximab and irinotecan</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m² to be administered every two weeks</description>
    <arm_group_label>iv cetuximab and irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Irinotecan eluting BEADS</intervention_name>
    <description>A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).</description>
    <arm_group_label>hepatic TACE with irinotecan eluting beads and iv cetuximab</arm_group_label>
    <other_name>DC Bead</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with confirmed diagnosis of stage IV (UICC) colorectal cancer with
             unresectable liver metastases (primary tumour may be present) and k-ras wild-type
             tumours

          2. Patients had been treated and shown to be refractory to 5-FU (Capecitabine
             allowed)/oxaliplatin and/or 5-FU/irinotecan. Prior therapy with VEGF-inhibitors (e.g
             bevacizumab) is allowed

          3. Patients with at least one measurable liver metastasis, with size &gt; 1cm (RECIST
             criteria)

          4. Patients with liver only or liver dominant disease (defined as ≥ 50 % tumour burden
             confined to the liver)

          5. Patients with a portal vein not interfering with transarterial chemoembolization (e.g.
             no thrombosis) as judged by the investigator

          6. ECOG Performance status ≤ 2

          7. Life expectancy &gt; 3 months

          8. Age ≥ 18 years.

          9. At least 4 weeks since last administration of last chemotherapy and/or radiotherapy
             (bone metastases may be allowed)

         10. Patients who received VEGF-inhibition (e.g. with bevacizumab) in prior therapy are
             eligible if stopped since 4-6 weeks before randomization

         11. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 75 x109/L

         12. INR &lt; 1.5 (patients on therapeutic anticoagulants are not eligible)

         13. Adequate liver function as measured by serum transaminases (AST &amp; ALT) ≤ 3 x ULN and
             total bilirubin ≤ 1.5 x ULN

         14. Adequate renal function: Serum creatinine ≤ 1.5 x ULN

         15. Normal level of serum magnesium

         16. Women of child bearing potential and fertile men are required to use effective
             contraception (negative serum βHCG for women of child-bearing age

         17. Signed, written informed consent

        Exclusion Criteria:

          1. Presence of CNS metastases

          2. Contraindications to irinotecan therapy (Chronic inflammatory bowel disease and/or
             bowel obstruction, history of severe hypersensitivity reactions to irinotecan
             hydrochloride trihydrate)

          3. Active bacterial, viral or fungal infection within 72 hours of study entry

          4. Women who are pregnant or breast feeding

          5. Allergy to contrast media

          6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years except
             adequately treated basal or squamous cell skin cancer or carcinoma in situ of the
             cervix

          7. Any contraindication for hepatic embolisation procedures:

               -  Large shunt as determined by the investigator (pretesting with lung perfusion
                  scan not required)

               -  Severe atheromatosis

               -  Hepatofugal blood flow

          8. Other significant medical or surgical condition, or any medication or treatment, that
             would place the patient at undue risk, that would preclude the safe use of
             chemoembolization or would interfere with study participation

          9. Known hypersensitivity or contraindication to the drugs used in the trial (eg:
             cetuximab, 5-HT3 receptor antagonist, dexamethasone, or any component of aprepitant)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Eppendorf, Universitäres Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH, Abteilung für Interventionelle Radiologie</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte, Klinik für Innere Medizin IV</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen, Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt</name>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Institut für Röntgendiagnostik</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Hans-Joachim Schmoll, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>colorectal</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>KRAS wildtype</keyword>
  <keyword>chemoembolization</keyword>
  <keyword>irinotecan eluting beads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

